Faes Farma : Q3 EBITDA a touch above. FY 2024 guidance nuanced to the high end
>Improving sales momentum is partially offset by SG&A inflation - Total Q3 revenues reached € 119m (+9% y-o-y vs 9% sales growth registered in Q2), a touch ahead of our estimate and the consensus. By division, sales of traditional products in Spain posted some sequential improvement (10% y-o-y in Q3 2024 vs 4% in Q2 and 14% in Q1), reflecting the positive impact that new formats are having in Bilastine that are offsetting the price reductions (+11% in Q3 vs -2% in Q2 ...Faes Farma is engaged in the health care research, manufacture and sale of prescription pharmaceuticals, over-the-counter pharmaceuticals and fine chemicals, URGO bandages and dressings and LAZLO cosmetics.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.